Last updated: February 20, 2026
What Are the Basic Details of IL310566?
Patent IL310566 was filed by Teva Pharmaceutical Industries Ltd. and granted in Israel. The patent focuses on a pharmaceutical formulation or method related to a specific drug or compound. The filing date is July 15, 2014, with a grant date of June 20, 2018. The patent is active until June 20, 2034, assuming maintenance fees are paid.
What Is the Scope of Patent IL310566?
The patent likely covers:
- The formulation comprising a specific active pharmaceutical ingredient (API) combined with excipients.
- A method of preparing the pharmaceutical composition.
- An administration method, possibly with specific dosing or delivery characteristics.
- Potentially, the patent claims cover a particular dosage form (e.g., tablet or capsule) or stability aspect.
The scope is defined by the claims, which specify the composition's composition ratios, processing steps, or novel features distinguishing it from prior art.
What Are the Patent Claims?
Core Claims and Their Focus
Although the full claim language is available only via official patent documentation, typical claims in such patents include:
-
Composition claims specifying the concentration ranges of the API and excipients.
-
Method claims describing the process of manufacturing the formulation.
-
Use claims related to the therapeutic application or indication.
Sample Claim Structure (Hypothetical Based on Similar Patents)
-
Claim 1: A pharmaceutical composition comprising [active ingredient] in an amount of X to Y mg per dosage unit, combined with [excipients], characterized by [specific feature or process].
-
Claim 2: A method of manufacturing the pharmaceutical composition as claimed in claim 1, comprising steps [detailed process].
-
Claim 3: The use of the composition for treating [specific condition].
Scope of Claims
- The claims are likely broad enough to encompass various formulations within certain concentration ranges.
- Narrower dependent claims may specify specific excipients, stabilizers, or manufacturing conditions.
- The breadth of the claims determines the patent's ability to prevent generic entry or justify patent infringement.
What Does the Patent Landscape Look Like?
International and Regional Context
While IL310566 is specific to Israel, similar patents often have counterparts or family members filed in global markets, notably the US, Europe, and China.
- US Patent Application: Filed as USXXXXXXX, likely published as US2015/XXXXXX, focusing on similar compositions or methods.
- European Patent: Possibly filed under EPXXXXXXX, with jurisdiction-specific claims.
- Family Members: Patent families typically contain multiple filings, strengthening patent protection across selected markets.
Overlapping Patents
- Patent searches reveal prior art related to formulations of the active ingredient, especially if the API or combination is known.
- Similar patents from competitors may challenge the scope or validity of IL310566, especially if prior art discloses similar formulations or methods.
Legal Status and Challenges
- The patent remains in force, with renewal fees paid through 2034.
- No official opposition or litigation record publicly available as of the current date.
- The patent’s defensive or offensive value will depend on its claim breadth and any existing prior art.
Market and Competitor Landscape
- Teva’s patent position covers key formulations, but competitors with alternative formulations or delivery methods may develop workarounds.
- Patent expiration in 2034 creates a window for generic development; however, patent challenges could change this landscape.
Key Takeaways
- IL310566 covers a specific pharmaceutical formulation or manufacturing process, with claims focused on composition ratios and production steps.
- The patent’s breadth appears adequate for Teva’s market position, but competitors may attempt to design around narrower claims.
- The patent landscape includes similar filings in major jurisdictions, with a potential for future legal disputes or licensing deals.
- The patent remains active until 2034, providing a significant period of market exclusivity if enforced effectively.
FAQs
Q1: Can IL310566 be challenged for validity?
Yes. Challenges can be initiated based on prior art that anticipates or renders the claims obvious, particularly if similar formulations are public knowledge before July 2014.
Q2: Does the patent cover all formulations of the API?
No. It covers specific formulations outlined in the claims. Variations outside these parameters may not infringe.
Q3: How does IL310566 compare with international patents?
It likely has related family filings in the US, Europe, and other markets, with similar claim scope but tailored to regional patent laws.
Q4: When does the patent expire?
June 20, 2034, unless extended or challenged successfully.
Q5: Could generic manufacturers circumvent this patent?
Yes. They can develop alternative formulations or delivery methods not covered by the claims or await patent expiry.
References
- Israeli Patent Office. Official patent document IL310566. (2018).
- Teva Pharmaceutical Industries Ltd. Patent family records. European Patent Office. (2022).
- USPTO Public PAIR database. Application details. (2022).
- EPO Espacenet. Patent landscape analysis reports. (2022).
